We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Discovery’s Surfaxin on Track for Complete Response in Early 2011
Discovery’s Surfaxin on Track for Complete Response in Early 2011
May 19, 2010
After a history of setbacks, Surfaxin is finally inching close to FDA approval for the prevention of respiratory distress syndrome in premature infants. Discovery Laboratories has completed the revalidation of a quality control and stability test required as part of an FDA complete response letter.